- Exchange: EN Brussels
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
ThromboGenics NV+ Add to Watchlist
THR:BB22.3650 EUR 0.3350 1.48%
As of 11:35:00 ET on 04/17/2014.
Company Profile for ThromboGenics NV (THR)
ThromboGenics NV is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company is focused on developing medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system.
Key Executives for ThromboGenics NV (THR)
|Gustaaf Van Reet "Staf"Chairman||Patrik De HaesCEO/Executive Director|
|Chris BuyseCFO/Executive Director/Secy||Koen KasChief Scientific Officer|
|David PearsonHead:Country Operations||Andy De DeeneHead:Program Mgmt|
|Aniz GirachHead:Clinical Ophthalmology||Ram PalankiHead:Marketing|
|Laurence RaemdonckHead:Human Resources||Christian JaeggiHead:Country Operations|